CELLCEPT (mycophenolate mofetil) by Roche is (mmf) is absorbed following oral administration and hydrolyzed to mycophenolic acid (mpa), the active metabolite. First approved in 1995.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
CellCept (mycophenolate mofetil) is an oral immunosuppressant that selectively inhibits inosine monophosphate dehydrogenase to block de novo guanosine nucleotide synthesis in lymphocytes. It is used primarily for organ transplant rejection prophylaxis and has extensive off-label use in autoimmune conditions. The mechanism shifts T and B lymphocytes from proliferation to anergy through suppression of Akt/mTOR and STAT5 pathways, preventing graft rejection.
Product approaching loss of exclusivity with moderate competitive pressure (score: 30), signaling contraction of brand team and shift toward generic transition planning.
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CELLCEPT at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CellCept offers career exposure to transplant immunology, managed care dynamics, and off-label marketing complexity; however, zero linked job postings and approaching LOE signal limited growth opportunity and team contraction risk. Best positioned for professionals seeking expertise in LOE transition management and generic defense strategy.